GB1348642A — Hypocholesterolaemic compositions
Assigned to Individual · Expires 1974-03-20 · 52y expired
What this patent protects
1348642 Hypocholesterolaemic composition A N HOWARD 13 Oct 1971 [15 Oct 1970] 49140/70 Heading ASB A hypocholesterolaemic composition comprises (a) a compound of formula in which R<SP>1</SP> and R<SP>2</SP> are separately H or C 1-6 alkyl or together with…
USPTO Abstract
1348642 Hypocholesterolaemic composition A N HOWARD 13 Oct 1971 [15 Oct 1970] 49140/70 Heading ASB A hypocholesterolaemic composition comprises (a) a compound of formula in which R<SP>1</SP> and R<SP>2</SP> are separately H or C 1-6 alkyl or together with the carbon atom to which they are linked represent a cycloalkyl radical, R<SP>3</SP> is phenyl or α-naphthyl optionally substituted with up to 3 halo, alkyl, alkenyl, alkoxy, aryl, alkaryl, aralkyl, aralkoxy or arylamino groups, X is O or NH, Y is an amino group or a group Z and Z is H, a cation or a residue of an esterified alcohol ZOH and (b) an anion exchange resin, the weight ratio (a):(b) being from 1:6 to 1:20. Component (a) may be α-(4-chlorophenoxy) isobutyric acid, α- (4-ethylphenoxy) isobutyric acid or a sodium, potassium, calcium, magnesium, iron or aluminium salt or a methyl, ethyl or n-propyl ester thereof. The ion-exchange resin may be (a) an #-aminoalkyl ether, #-dialkylaminoalkyl ether, #-guanidinoalkyl ether or #-p-aminophenylalkyl ether of dextran or cellulose cross-linked with epichlorohydrin, all alkyl groups having 1 to 4 carbon atoms, (b) a condensation polymer of a poly(ethylene imine) and epichlorohydrin, glycerol, 1,3-dichlorohydrin or an aliphatic bis-epoxy compound, (c) a styrene divinyl benzene copolymer containing quaternary ammonium groups or (d) an addition polymer of a compound of formula in which R is H, methyl, phenyl, carboxylic acid, methoxycarbonyl or ethoxycarbonyl, R' is methyl or -CH 2 COOX wherein X is H or C 1-4 alkyl and Z is pyridinium or a carboxylic ester group which includes a quaternary ammonium group but is free of aliphatic unsaturation. The composition may also include taurine and a carrier. It may be in the form of powder, tablets, capsules, an oil suspension or an aqueous suspension. Component (a) may be separately enclosed in microcapsules.
Drugs covered by this patent
- Bylvay (ODEVIXIBAT) · Ipsen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.